<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Given its catalytic activity to generate diacylglycerol and <z:chebi fb="1" ids="24848">inositol</z:chebi> 1,4,5-trisphosphate, phospholipase C (PLC) is implicated in promoting cell growth </plain></SENT>
<SENT sid="1" pm="."><plain>However, we found that PLC-beta3-deficient mice develop <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath>, <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The mutant mice have <z:mp ids='MP_0004809'>increased numbers of hematopoietic stem cells</z:mp> with increased proliferative, survival, and myeloid-differentiative abilities </plain></SENT>
<SENT sid="3" pm="."><plain>These properties are dependent on Stat5 and can be antagonized by the protein phosphatase SHP-1 </plain></SENT>
<SENT sid="4" pm="."><plain>Stat5-dependent cooperative transformation by active c-Myc and PLC-beta3 deficiency was suggested in mouse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in PLC-beta3(-/-) and in Emicro-myc;PLC-beta3(+/-) mice and human Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="5" pm="."><plain>The same mechanism for <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> seems to be operative in other human lymphoid and <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, PLC-beta3 is likely a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor </plain></SENT>
</text></document>